Carnivac-Cov has undergone clinical trials in dogs, cats, mink and other animals from October, Rosselkhoznadzor said in a statement to the Russian Federal Veterinary Oversight Service.
“The results allow us to conclude that the vaccine is harmless and has high immunogenicity, since all of the animals tested developed anti-coronavirus antibodies 100% of the time,” said Savenkov.
He added that scientists are still studying the long-term effectiveness of Carnivac-Cov, although it is believed to confer protective immunity in pets for at least six months.
“Russian scientists believe that the use of the vaccine can prevent the virus from mutating, which most often occurs during interspecies transmission,” said Rosselkhoznadzor.
Carnivac-Cov is expected to cost around 500 rubles ($ 6.60), Rosselkhoznadzor reportedly said.
Experts have said pets can be infected with Covid-19 but not transmit it to humans.
A number of animals around the world have reportedly tested positive for Covid-19, including the millions of mink slaughtered in Denmark and the Netherlands amid fears of the first known animal-to-human transmission.
Rosselkhoznadzor’s announcement follows a World Health Organization (WHO) expert report released on Monday saying it was “likely very likely” that Covid-19 had passed from bats to humans via a intermediate host still unknown. Initial suspicion fell on endangered pangolin snakes and anteaters as the “missing link” of the global pandemic.
The agency said agricultural companies from countries including the United States, Canada and Singapore, as well as Austria, Greece and Poland, have expressed interest in Carnivac-Cov.
Russia has rolled out three human vaccines against Covid-19 so far, although its national vaccination campaign has lagged behind in widespread skepticism of local vaccines.